As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

Context

All about an attempt to end the pandemic across the globe with the help of vaccinations for COVID-19. It is important to track and understand the effort that is in progress across the globe to administer doses of vaccinations. There could be many sources of information. This is one of the sources from Bloomberg that is captured and presented here. Additionally, I have tried to include the GDP per capita per country from Wiki so that we can see how that is influencing the vaccination progress.

Content

There are two files. a) Latest Global Covid-19 Vaccine tracker of all the countries and regions in the World as of September 11, 2021 b) GDP information per capita per country

Attribute Information (COVID19 vaccination Tracker file)

• Countries and regions - Name of countries
• Doses administered - Number of vaccine doses administered
• Enough for % of people - Number of vaccine doses administered as a % of population
• Percentage of population with 1+ dose - Percentage of the population vaccinated with at least 1+ dose
• Percentage of the population fully vaccinated - Percentage of the population fully vaccinated
• Daily rate of doses administered - Daily rate of doses administered

Attribute Information (for GDP file per country per capita)

• Country
• Subregion (Western Europe, Northern Europe etc.)
• Region (Europe, Asia etc.)
• GDP estimate $ as per IMF
• Year for IMF
• GDP estimate $ as per UN
• Year for UN
• GDP estimate $ as per World Bank
• Year for World Bank

Source

URL1: https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/ URL2: https://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal)_per_capita

Inspiration

The path to immunity and hope to get back to normalcy by tracking and analyzing the latest updates on vaccinations across the globe. As we gear up to end the pandemic, the vaccination tracker can help us answer the following questions.

• What are the Top N countries/regions where vaccinations are administered?
• What are the Top N countries/regions with fully vaccinated people?
• What are the Top N countries/regions with at least 1+ doses administered?
• What is the access to vaccines - by least wealthy and most wealthy countries? (based on GDP per capita per country data)
• What is the average daily rate of the dose administered? Which countries are Top N and Bottom N? Which countries are above and below the World average? and many more...

Thank you for reading.

Please give your feedback/upvote/comments if you find this useful and download.

As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

Context

After observing many naive conversations about COVID-19, claiming that the pandemic can be blamed on just a few factors, I decided to create a data set, to map a number of different data points to every U.S. state (including D.C. and Puerto Rico).

Content

This data set contains basic COVID-19 information about each state, such as total population, total COVID-19 cases, cases per capita, COVID-19 deaths and death rate, Mask mandate start, and end dates, mask mandate duration (in days), and vaccination rates.

However, when evaluating a pandemic (specifically a respiratory virus) it would be wise to also explore the population density of each state, which is also included. For those interested, I also included political party affiliation for each state ("D" for Democrat, "R" for Republican, and "I" for Puerto Rico). Vaccination rates are split into 1-dose and 2-dose rates.

Also included is data ranking the Well-Being Index and Social Determinantes of Health Index for each state (2019). There are also several other columns that "rank" states, such as ranking total cases per state (ascending), total cases per capita per state (ascending), population density rank (ascending), and 2-dose vaccine rate rank (ascending). There are also columns that compare deviation between columns: case count rank vs population density rank (negative numbers indicate that a state has more COVID-19 cases, despite being lower in population density, while positive numbers indicate the opposite), as well as per-capita case count vs density.

Acknowledgements

Several Statista Sources: * COVID-19 Cases in the US * Population Density of US States * COVID-19 Cases in the US per-capita * COVID-19 Vaccination Rates by State

Other sources I'd like to acknowledge: * Ballotpedia * DC Policy Center * Sharecare Well-Being Index * USA Facts * World Population Overview

Inspiration

I would like to see if any new insights could be made about this pandemic, where states failed, or if these case numbers are 100% expected for each state.

Vaccination is widely considered to be one of the most important prevention measures as a health strategy. This paper examines trends in basic childhood vaccination coverage and which country and time-dependent determinants may have influenced childhood immunization rates (1-dose BCG, 1- and 3-dose DTP (diphtheria, tetanus, pertussis), 1-dose measles, and 3-dose polio) between 1980 and 2020 across 94 countries. We identify economic, inequality, demographic, health, education, labor market, environmental, and political stability factors of immunization. To do this, we use data from the annual WHO and United Nations International Children’s Emergency Fund (UNICEF) coverage estimates. The empirical analysis consists of generalized estimating equation models to assess relationships between immunization rates and socioeconomic factors. Additionally, we follow the Barro and Sala-i-Martín approach to identify conditional convergence. Our findings show the strongest positive statistically significant association between immunization rates and GDP per capita, as well as births attended by skilled health staff. Moreover, our research demonstrates conditional convergence, indicating that countries converge towards different steady states. The present study brings new insights to investigating the determinants of childhood vaccination coverage and provides significant implications for health policies.

Global Covid-19 Data

Global Covid-19 data on cases, deaths, vaccinations, and more

By Valtteri Kurkela [source]

About this dataset

The dataset is constantly updated and synced hourly to ensure up-to-date information. With over several columns available for analysis and exploration purposes, users can extract valuable insights from this extensive dataset.

Some of the key metrics covered in the dataset include:

1. Vaccinations: The dataset covers total vaccinations administered worldwide as well as breakdowns of people vaccinated per hundred people and fully vaccinated individuals per hundred people.

2. Testing & Positivity: Information on total tests conducted along with new tests conducted per thousand people is provided. Additionally, details on positive rate (percentage of positive Covid-19 tests out of all conducted) are included.

3. Hospital & ICU: Data on ICU patients and hospital patients are available along with corresponding figures normalized per million people. Weekly admissions to intensive care units and hospitals are also provided.

4. Confirmed Cases: The number of confirmed Covid-19 cases globally is captured in both absolute numbers as well as normalized values representing cases per million people.

5.Confirmed Deaths: Total confirmed deaths due to Covid-19 worldwide are provided with figures adjusted for population size (total deaths per million).

6.Reproduction Rate: The estimated reproduction rate (R) indicates the contagiousness of the virus within a particular country or region.

7.Policy Responses: Besides healthcare-related metrics, this comprehensive dataset includes policy responses implemented by countries or regions such as lockdown measures or travel restrictions.

8.Other Variables of InterestThe data encompasses various socioeconomic factors that may influence Covid-19 outcomes including population density,membership in a continent,gross domestic product(GDP)per capita;

For demographic factors: -Age Structure : percentage populations aged 65 and older,aged (70)older,median age -Gender-specific factors: Percentage of female smokers -Lifestyle-related factors: Diabetes prevalence rate and extreme poverty rate

1. Excess Mortality: The dataset further provides insights into excess mortality rates, indicating the percentage increase in deaths above the expected number based on historical data.

The dataset consists of numerous columns providing specific information for analysis, such as ISO code for countries/regions, location names,and units of measurement for different parameters.

Overall,this dataset serves as a valuable resource for researchers, analysts, and policymakers seeking to explore various aspects related to Covid-19

How to use the dataset

Introduction:

• Understanding the Basic Structure:

  • The dataset consists of various columns containing different data related to vaccinations, testing, hospitalization, cases, deaths, policy responses, and other key variables.
  • Each row represents data for a specific country or region at a certain point in time.

• Selecting Desired Columns:

  • Identify the specific columns that are relevant to your analysis or research needs.
  • Some important columns include population, total cases, total deaths, new cases per million people, and vaccination-related metrics.

• Filtering Data:

  • Use filters based on specific conditions such as date ranges or continents to focus on relevant subsets of data.
  • This can help you analyze trends over time or compare data between different regions.

• Analyzing Vaccination Metrics:

  • Explore variables like total_vaccinations, people_vaccinated, and people_fully_vaccinated to assess vaccination coverage in different countries.
  • Calculate metrics such as people_vaccinated_per_hundred or total_boosters_per_hundred for standardized comparisons across populations.

• Investigating Testing Information:

  • Examine columns such as total_tests, new_tests, and tests_per_case to understand testing efforts in various countries.
  • Calculate rates like tests_per_case to assess testing efficiency or identify changes in testing strategies over time.

• Exploring Hospitalization and ICU Data:

  • Analyze variables like hosp_patients, icu_patients, and hospital_beds_per_thousand to understand healthcare systems' strain.
  • Calculate rates like icu_patients_per_million or hosp_patients_per_million for cross-country comparisons.

• Assessing Covid-19 Cases and Deaths:

  • Analyze variables like total_cases, new_ca...

Vaccination is considered as the main tool for the Global Control and Eradication Strategy for peste des petits ruminants (PPR), and the efficacity of the PPR-vaccine in conferring long-life immunity has been established. Despite this, previous studies asserted that vaccination can be expensive and consequently, the effectiveness of disease control may not necessarily translate to overall profit for farmers. Also, the consequences of PPR control on socioeconomic indicators like food and nutrition security at a macro-national level have not been explored thoroughly. Therefore, this study seeks to assess ex-ante the impact of PPR control strategies on farm-level profitability and the socioeconomic consequences concerning food and nutrition security at a national level in Senegal. A bi-level system dynamics model, compartmentalised into five modules consisting of integrated production-epidemiological, economics, disease control, marketing, and policy modules, was developed with the STELLA Architect software, validated, and simulated for 30 years at a weekly timestep. The model was parameterised with data from household surveys from pastoral areas in Northern Senegal and relevant existing data. Nine vaccination scenarios were examined considering different vaccination parameters (vaccination coverage, vaccine wastage, and the provision of government subsidies). The findings indicate that compared to a no-vaccination scenario, all the vaccination scenarios for both 26.5% (actual vaccination coverage) and 70% (expected vaccination coverage) resulted in statistically significant differences in the gross margin earnings and the potential per capita consumption for the supply of mutton and goat meat. At the prevailing vaccination coverage (with or without the provision of government subsidies), farm households will earn an average gross margin of $69.43 (annually) more than without vaccination, and the average per capita consumption for mutton and goat meat will increase by 1.13kg/person/year. When the vaccination coverage is increased to the prescribed threshold for PPR eradication (i.e., 70%), with or without the provision of government subsidies, the average gross margin earnings would be $72.23 annually and the per capita consumption will increase by 1.23kg/person/year compared to the baseline (without vaccination). This study’s findings offer an empirical justification for a sustainable approach to PPR eradication. The information on the socioeconomic benefits of vaccination can be promoted via sensitization campaigns to stimulate farmers’ uptake of the practice. This study can inform investment in PPR control.

Veterinary Vaccines Except for Foot and Mouth Market Size Value Per Capita in the US, 2021 Discover more data with ReportLinker!

BackgroundThe global COVID-19 pandemic is still ongoing, and cross-country and cross-period variation in COVID-19 age-adjusted case fatality rates (CFRs) has not been clarified. Here, we aimed to identify the country-specific effects of booster vaccination and other features that may affect heterogeneity in age-adjusted CFRs with a worldwide scope, and to predict the benefit of increasing booster vaccination rate on future CFR.MethodCross-temporal and cross-country variations in CFR were identified in 32 countries using the latest available database, with multi-feature (vaccination coverage, demographic characteristics, disease burden, behavioral risks, environmental risks, health services and trust) using Extreme Gradient Boosting (XGBoost) algorithm and SHapley Additive exPlanations (SHAP). After that, country-specific risk features that affect age-adjusted CFRs were identified. The benefit of booster on age-adjusted CFR was simulated by increasing booster vaccination by 1–30% in each country.ResultsOverall COVID-19 age-adjusted CFRs across 32 countries ranged from 110 deaths per 100,000 cases to 5,112 deaths per 100,000 cases from February 4, 2020 to Jan 31, 2022, which were divided into countries with age-adjusted CFRs higher than the crude CFRs and countries with age-adjusted CFRs lower than the crude CFRs (n = 9 and n = 23) when compared with the crude CFR. The effect of booster vaccination on age-adjusted CFRs becomes more important from Alpha to Omicron period (importance scores: 0.03–0.23). The Omicron period model showed that the key risk factors for countries with higher age-adjusted CFR than crude CFR are low GDP per capita and low booster vaccination rates, while the key risk factors for countries with higher age-adjusted CFR than crude CFR were high dietary risks and low physical activity. Increasing booster vaccination rates by 7% would reduce CFRs in all countries with age-adjusted CFRs higher than the crude CFRs.ConclusionBooster vaccination still plays an important role in reducing age-adjusted CFRs, while there are multidimensional concurrent risk factors and precise joint intervention strategies and preparations based on country-specific risks are also essential.

As of April 26, 2023, around 81.3 percent of the U.S. population had received at least one dose of a COVID-19 vaccination. This statistic shows the percentage of the population in the United States who had been given a COVID-19 vaccination as of April 26, 2023, by state or territory.

Vaccine Delivery Devices Market Outlook

According to our latest research, the Global Vaccine Delivery Devices market size was valued at $5.1 billion in 2024 and is projected to reach $9.8 billion by 2033, expanding at a robust CAGR of 7.2% during 2024–2033. The surge in demand for immunization programs, combined with the increasing prevalence of infectious diseases and the rapid advancement of vaccine technology, is a major factor fueling the growth of the vaccine delivery devices market globally. As governments and healthcare organizations intensify efforts to prevent disease outbreaks and pandemics, the need for efficient, safe, and user-friendly vaccine delivery solutions is at an all-time high. This is further bolstered by innovations such as microneedle patches and jet injectors, which are revolutionizing the landscape by enabling less invasive and more accessible vaccination, thus driving adoption across both developed and emerging economies.

Regional Outlook

North America continues to dominate the vaccine delivery devices market, accounting for the largest share of global revenue in 2024. The region’s mature healthcare infrastructure, high per capita healthcare expenditure, and strong governmental support for immunization initiatives have established a robust foundation for market growth. Additionally, the presence of leading medical device manufacturers and continuous technological innovations, such as the integration of smart syringes and painless delivery systems, have further cemented North America's leadership. The United States, in particular, benefits from proactive vaccination policies, comprehensive insurance coverage, and a strong focus on biopharmaceutical research and development, all of which contribute to sustained demand for advanced vaccine delivery devices across hospitals, clinics, and home care settings.

Asia Pacific is emerging as the fastest-growing region in the vaccine delivery devices market, with a projected CAGR exceeding 9.5% during the forecast period. This rapid acceleration is primarily driven by increasing government investments in healthcare infrastructure, expanding immunization coverage, and rising awareness of vaccine-preventable diseases. Countries such as China, India, and Japan are witnessing significant growth in vaccination rates, supported by large-scale public health campaigns and international collaborations with organizations like WHO and UNICEF. Furthermore, the region is experiencing a surge in local manufacturing capacity and the adoption of innovative delivery technologies, making vaccines more accessible in both urban and rural settings. Strategic partnerships and the entrance of regional players are also intensifying competition, leading to improved product availability and affordability.

In emerging economies across Latin America, the Middle East, and Africa, the adoption of vaccine delivery devices is gaining traction, albeit at a varied pace due to infrastructural and economic challenges. While these regions are benefitting from global vaccine initiatives and donor-funded programs, issues such as limited cold chain logistics, insufficient healthcare personnel, and variable regulatory environments continue to impede widespread adoption. Nonetheless, localized demand is growing as governments implement targeted immunization drives to combat outbreaks of diseases such as measles, polio, and influenza. Efforts to improve healthcare access and introduce cost-effective, easy-to-use delivery devices are expected to gradually bridge the gap and unlock new growth opportunities in these markets.

Report Scope

Veterinary Vaccines Except for Foot and Mouth Market Size Value Per Capita in Japan, 2021 Discover more data with ReportLinker!

Veterinary Vaccines Except for Foot and Mouth Market Size Value Per Capita in Colombia, 2021 Discover more data with ReportLinker!

BackgroundMaternal influenza immunization has gained traction as a strategy to diminish maternal and neonatal mortality. However, efforts to vaccinate pregnant women against influenza in developing countries will require substantial investment. We present cost-effectiveness estimates of maternal influenza immunization based on clinical trial data from Bamako, Mali.MethodsWe parameterized a decision-tree model using prospectively collected trial data on influenza incidence, vaccine efficacy, and direct and indirect influenza-related healthcare expenditures. Since clinical trial participants likely had better access to care than the general Malian population, we also simulated scenarios with poor access to care, including decreased healthcare resource utilization and worse influenza-related outcomes.ResultsUnder base-case assumptions, a maternal influenza immunization program in Mali would cost $857 (95% UI: $188-$2358) per disability-adjusted life year (DALY) saved. Adjusting for poor access to care yielded a cost-effectiveness ratio of $486 (95% UI: $105-$1425) per DALY saved. Cost-effectiveness ratios were most sensitive to changes in the cost of a maternal vaccination program and to the proportion of laboratory-confirmed influenza among infants warranting hospitalization. Mean cost-effectiveness estimates fell below Mali’s GDP per capita when the cost per pregnant woman vaccinated was $1.00 or less with no adjustment for access to care or $1.67 for those with poor access to care. Healthcare expenditures for lab-confirmed influenza were not significantly different than the cost of influenza-like illness.ConclusionsMaternal influenza immunization in Mali would be cost-effective in most settings if vaccine can be obtained, managed, and administered for ≤$1.00 per pregnant woman.

Context

Covid-19 Data collected from various sources on the internet. This dataset has daily level information on the number of affected cases, deaths, and recovery from the 2019 novel coronavirus. Please note that this is time-series data and so the number of cases on any given day is the cumulative number.

Content

The dataset includes 28 files scrapped from various data sources mainly the John Hopkins GitHub repository, the ministry of health affairs India, worldometer, and Our World in Data website. The details of the files are as follows

• countries-aggregated.csv A simple and cleaned data with 5 columns with self-explanatory names. -covid-19-daily-tests-vs-daily-new-confirmed-cases-per-million.csv A time-series data of daily test conducted v/s daily new confirmed case per million. Entity column represents Country name while code represents ISO code of the country. -covid-contact-tracing.csv Data depicting government policies adopted in case of contact tracing. 0 -> No tracing, 1-> limited tracing, 2-> Comprehensive tracing. -covid-stringency-index.csv The nine metrics used to calculate the Stringency Index are school closures; workplace closures; cancellation of public events; restrictions on public gatherings; closures of public transport; stay-at-home requirements; public information campaigns; restrictions on internal movements; and international travel controls. The index on any given day is calculated as the mean score of the nine metrics, each taking a value between 0 and 100. A higher score indicates a stricter response (i.e. 100 = strictest response). -covid-vaccination-doses-per-capita.csv A total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). -covid-vaccine-willingness-and-people-vaccinated-by-country.csv Survey who have not received a COVID vaccine and who are willing vs. unwilling vs. uncertain if they would get a vaccine this week if it was available to them. -covid_india.csv India specific data containing the total number of active cases, recovered and deaths statewide. -cumulative-deaths-and-cases-covid-19.csv A cumulative data containing death and daily confirmed cases in the world. -current-covid-patients-hospital.csv Time series data containing a count of covid patients hospitalized in a country -daily-tests-per-thousand-people-smoothed-7-day.csv Daily test conducted per 1000 people in a running week average. -face-covering-policies-covid.csv Countries are grouped into five categories: 1->No policy 2->Recommended 3->Required in some specified shared/public spaces outside the home with other people present, or some situations when social distancing not possible 4->Required in all shared/public spaces outside the home with other people present or all situations when social distancing not possible 5->Required outside the home at all times regardless of location or presence of other people -full-list-cumulative-total-tests-per-thousand-map.csv Full list of total tests conducted per 1000 people. -income-support-covid.csv Income support captures if the government is covering the salaries or providing direct cash payments, universal basic income, or similar, of people who lose their jobs or cannot work. 0->No income support, 1->covers less than 50% of lost salary, 2-> covers more than 50% of the lost salary. -internal-movement-covid.csv Showing government policies in restricting internal movements. Ranges from 0 to 2 where 2 represents the strictest. -international-travel-covid.csv Showing government policies in restricting international movements. Ranges from 0 to 2 where 2 represents the strictest. -people-fully-vaccinated-covid.csv Contains the count of fully vaccinated people in different countries. -people-vaccinated-covid.csv Contains the total count of vaccinated people in different countries. -positive-rate-daily-smoothed.csv Contains the positivity rate of various countries in a week running average. -public-gathering-rules-covid.csv Restrictions are given based on the size of public gatherings as follows: 0->No restrictions 1 ->Restrictions on very large gatherings (the limit is above 1000 people) 2 -> gatherings between 100-1000 people 3 -> gatherings between 10-100 people 4 -> gatherings of less than 10 people -school-closures-covid.csv School closure during Covid. -share-people-fully-vaccinated-covid.csv Share of people that are fully vaccinated. -stay-at-home-covid.csv Countries are grouped into four categories: 0->No measures 1->Recommended not to leave the house 2->Required to not leave the house with exceptions for daily exercise, grocery shopping, and ‘essent...

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

IntroductionInequitable access to COVID-19 vaccines among countries is a pressing global health issue. Factors such as economic power, political power, political stability, and health system strength contribute to disparities in vaccine distribution. This study aims to assess the inequality in vaccine distribution among countries based on these factors and identify their relationship with COVID-19 vaccine distribution.MethodsA Concentration Index (CI) analysis was conducted to evaluate inequalities in the distribution of COVID-19 vaccines among countries based on four separate variables: GDP per capita, political stability (PS), World Power Index (WPI), and Universal Health Coverage (UHC). Additionally, Multiple Linear Regression (MLR) analysis was employed to explore the relationship between vaccine distribution and these independent variables. Two vaccine distribution variables were utilized for result reliability.ResultsThe analysis revealed significant inequalities in COVID-19 vaccine distribution according to the countries’ GDP/capita, PS, WPI, and UHC. However, the multiple linear regression analysis showed that there is no significant relationship between COVID-19 vaccine distribution and the countries’ GDP/capita and that UHC is the most influential factor impacting COVID-19 vaccine distribution and accessibility.DiscussionThe findings underscore the complex interplay between economic, political, and health system factors in shaping vaccine distribution patterns. To improve the accessibility to vaccines in future pandemics, Global Health Governance (GHG) and countries should consider working on three areas; enhance political stabilities in countries, separate the political power from decision-making at the global level and most importantly support countries to achieve UHC.

Veterinary Vaccines Except for Foot and Mouth Market Size Value Per Capita in Mexico, 2021 Discover more data with ReportLinker!